AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Nexium (esomeprazole) — Established RoW YoY CER by Year
Nexium (esomeprazole) — Established RoW YoY CER (%) (%)
AstraZeneca Nexium (esomeprazole) — Established RoW YoY CER: -26.0% in FY2025, up 10.0 pts from a year earlier.
Latest, FY2025
-26.0%
Period ended Dec 31, 2025
Change on a year earlier
+10.0 pts
-36.0% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Nexium | 816 | (6) | (5) | 67 | (30) | 611 | 3 | 5 | 50 | (18) | (20) | 88 | (26) | (26)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Nexium (esomeprazole) — Established RoW YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -26.0% | +10.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | -36.0% | +25.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | -61.0% | -111.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 50.0% | +62.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | -12.0% | -20.0 pts | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 8.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Nexium (esomeprazole) — Established RoW YoY CER (%), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-nexium-erow-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.